Clinical trials
Newly Diagnosed clinical trials
Below are recruiting newly diagnosed clinical trials, each written for real people, not researchers. We’re tracking 395 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05864534RecruitingPhase 2
Ultrasound plus immune treatment after new glioblastoma diagnosis
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Chicago, IllinoisAges 18 years+ - NCT05734560RecruitingPhase 1/Phase 2
Study drug via brain catheter for newly diagnosed GBM
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
Durham, North CarolinaAges 18 years+ - NCT05506410Recruiting
Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Zhengzhou, HenanAges 18–90 - NCT05520892RecruitingPhase 4
IVIG dose options for newly diagnosed childhood ITP
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Fuzhou, FujianAges 4 weeks–14 years - NCT07296627Recruiting
Real-world immunotherapy for newly diagnosed multiple myeloma
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07087964Recruiting
PET scans to better understand multiple myeloma risk and disease
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
Antwerp, AntwerpenAges 18 years+ - NCT07143812RecruitingPhase 1
Stem cell gene therapy for newly diagnosed glioblastoma
This trial tests a new stem cell-based gene therapy for people with newly diagnosed glioblastoma who have already received standard treatment. The goal is to see if it is safe and potentially effective.
Seongnam, KyunggidoAges 19–70 - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT06682156Recruiting
Switching to carfilzomib for multiple myeloma patients who can't tolerate bortezomib
This trial is for people newly diagnosed with multiple myeloma who are having side effects from their first treatment with bortezomib. It tests switching to a different drug called carfilzomib to see if it works well with fewer side effects.
Suzhou, JiangsuAges 18 years+ - NCT07652138RecruitingPhase 1
RN1201 injection for newly diagnosed multiple myeloma
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Suzhou, JiangsuAges 18–70 - NCT06553352RecruitingPhase 2
Zanubrutinib with obinutuzumab for new follicular lymphoma
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
Xiamen, FujianAges 18 years+ - NCT07172204RecruitingPhase 2
Alternating chemo drugs for older or frailer adults with new AML
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT05833893RecruitingPhase 2
Selinexor plus COPL for newly diagnosed advanced NK/T lymphoma
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Beijing, HaidianAges 14 years+ - NCT06758375RecruitingPhase 2
Low dose teclistamab for newly diagnosed multiple myeloma
This trial tests a lower dose of the drug teclistamab in people newly diagnosed with multiple myeloma. It aims to see if a lower dose is still effective and has fewer side effects.
Monterrey, Nuevo LeónAges 18 years+ - NCT06825182RecruitingPhase 3
Islet alpha cell function in new type 2 diabetes
This trial looks at how certain cells in the pancreas work in people newly diagnosed with type 2 diabetes. It may help doctors understand the disease better and find new treatment approaches.
Nanjing, JiangsuAges 18 years+ - NCT07474142Recruiting
PSMA PET scan for newly diagnosed prostate cancer
This study looks at whether a special scan called PSMA PET can help predict how prostate cancer will progress. It is for people who have just been diagnosed and have not started treatment yet.
Lanzhou, GansuAges 18–100 - NCT06683885RecruitingPhase 1/Phase 2
Targeted drug combo for elderly DLBCL patients
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Zhengzhou, HenanAges 65 years+ - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
Hartford, ConnecticutAges 18–80 - NCT05566054RecruitingPhase 2
Newly diagnosed AML-M5 treated with VAC drug combination
This Phase 2 trial studies a combination of Venetoclax, Azacitidine, and Chidamide (VAC) for newly diagnosed acute monocytic leukemia (AML-M5). It may help people who cannot safely receive standard “intensive chemotherapy” because of age or other health problems.
Suzhou, JiangsuAges 18 years+ - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+ - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT07561892RecruitingPhase 4
Chemotherapy with or without silibinin for newly diagnosed blood cancer
This trial tests whether adding silibinin (a plant-based supplement) to standard chemotherapy drugs (daunorubicin or idarubicin) helps treat newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The goal is to see if this combination is more effective and safer than chemotherapy alone.
Fuzhou, FujianAges 18–65
Hear when a new Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed?
- Yes. Clin2 currently lists 395 recruiting newly diagnosed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.